AKT activation is a feature of CALR mutant myeloproliferative neoplasms
暂无分享,去创建一个
A. Tefferi | Q. Wen | T. Lasho | Marinka Bulic | J. Crispino | Te Ling | C. Marinaccio | C. fu | Wei Chen | K. Xu | C. Fu | Chunling Fu
[1] G. Hobbs,et al. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. , 2017, Hematology/oncology clinics of North America.
[2] K. Nagata,et al. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib , 2016, Leukemia.
[3] U. McDermott,et al. A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation , 2016, Leukemia.
[4] T. Brümmendorf,et al. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion , 2016, Journal of Hematology & Oncology.
[5] F. Al-Shahrour,et al. Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. , 2016, Cancer discovery.
[6] C. Pecquet,et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. , 2016, Blood.
[7] C. Pecquet,et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. , 2016, Blood.
[8] A. Tefferi,et al. Definition and management of ruxolitinib treatment failure in myelofibrosis , 2014, Blood Cancer Journal.
[9] Qiang Wen,et al. AKT is a therapeutic target in myeloproliferative neoplasms , 2013, Leukemia.